

## Overview

### Useful For

Diagnosis of alpha-mannosidosis

This test is **not useful for** establishing carrier status for alpha-mannosidosis.

### Genetics Test Information

Alpha-mannosidosis is an autosomal recessive lysosomal storage disorder caused by reduced or absent acid alpha-mannosidase enzyme activity.

Determining enzymatic activity is the next step of the diagnostic workup for an individual clinically suspicious for an oligosaccharidosis with a positive screening result suggestive of alpha-mannosidosis.

### Special Instructions

- [Informed Consent for Genetic Testing](#)
- [Biochemical Genetics Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)

### Method Name

Fluorometric

### NY State Available

Yes

## Specimen

### Specimen Type

Whole Blood ACD

### Ordering Guidance

If clinically suspicious of an oligosaccharidosis, a screening test is available. Order OLIGU / Oligosaccharide Screen, Random, Urine.

### Shipping Instructions

**For optimal isolation of leukocytes, it is recommended the specimen arrive refrigerate within 6 days of collection to be stabilized.** Collect specimen Monday through Thursday only and not the day before a holiday. Specimen should be collected and packaged as close to shipping time as possible.

### Specimen Required

**Container/Tube:**

**Preferred:** Yellow top (ACD solution B)

**Acceptable:** Yellow top (ACD solution A)

**Specimen Volume:** 6 mL

**Collection Instructions:** Send specimen in original tube. **Do not aliquot.**

### Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

[-Informed Consent for Genetic Testing \(T576\)](#)

[-Informed Consent for Genetic Testing-Spanish \(T826\)](#)

2. [Biochemical Genetics Patient Information \(T602\)](#)

3. If not ordering electronically, complete, print, and send a [Biochemical Genetics Test Request \(T798\)](#) with the specimen.

### Specimen Minimum Volume

5 mL

### Reject Due To

Gross hemolysis	Reject
-----------------	--------

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole Blood ACD	Ambient	6 days	YELLOW TOP/ACD
	Refrigerated (preferred)	6 days	YELLOW TOP/ACD

### Clinical & Interpretive

#### Clinical Information

Alpha-mannosidosis is an autosomal recessive lysosomal storage disorder caused by reduced or absent acid alpha-mannosidase enzyme activity. This enzyme is involved in glycoprotein catabolism, with absent or reduced activity resulting in the accumulation of undigested mannose-containing complex oligosaccharides in the lysosomes, disrupting the normal functioning of cells.

Clinical features and severity of symptoms are widely variable within alpha-mannosidosis but, in general, the disorder is characterized by skeletal abnormalities, immune deficiency, hearing impairment, and intellectual disability. Three clinical subtypes of the disorder have been described and vary with respect to age of onset and clinical presentation. Type 1 is generally classified by a mild presentation and slow progression with onset after 10 years of age and absence of skeletal abnormalities. Type 2 is generally a more moderate form with slow progression and onset prior to 10 years of age with skeletal abnormalities and myopathy. Type 3 is the most severe form with onset in early infancy, skeletal abnormalities such as dysostosis multiplex, and severe central nervous system involvement. Although treatment is mostly supportive and aimed at preventing complications, hematopoietic stem cell transplant has been reported to be a feasible therapeutic option. The incidence of alpha-mannosidosis is estimated at 1 in 500,000 live births.

An initial diagnostic workup may include a screening assay for several oligosaccharides in urine, OLIGU / Oligosaccharide Screen, Random, Urine. If the urine oligosaccharide screening assay is suggestive of alpha-mannosidosis, enzyme analysis of acid alpha-mannosidase can confirm the diagnosis. Molecular analysis of the *MAN2B1* gene allows for detection of a disease-causing variant in affected individuals and subsequent carrier detection in relatives (see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing; specify *MAN2B1* gene list ID: IEMCP-MUMNLV).

**Reference Values**

> or =0.54 nmol/min/mg protein

**Interpretation**

Values below 0.54 nmol/min/mg protein are consistent with a diagnosis of alpha-mannosidosis.

**Cautions**

No significant cautionary statements

**Clinical Reference**

1. Malm D, Nilssen O: Alpha-mannosidosis. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle. 2001. Updated July 18, 2019. Accessed February 18, 2022. Available at [www.ncbi.nlm.nih.gov/books/NBK1396/](http://www.ncbi.nlm.nih.gov/books/NBK1396/)
2. Thomas GH: Disorders of glycoprotein degradation: alpha-mannosidosis, beta-mannosidosis, fucosidosis, and sialidosis. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed February 18, 2022. Available at <https://ommbid.mhmedical.com/content.aspx?sectionid=225545029>
3. Mynarek M, Tolar J, Albert MH, et al: Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplant. 2012 Mar;47(3):352-359. doi: 10.1038/bmt.2011.99
4. Guffon N, Tylki-Szymanska AT, Borgwardt L, et al: Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019 Apr;126(4):470-474. doi: 10.1016/j.ymgme.2019.01.024

**Performance****Method Description**

The deficiency of alpha-D-mannosidase is demonstrable using the artificial substrate 4-methylumbelliferol alpha-D-mannopyranoside. (Gehler J, Cantz M, Tolksdorf M, Spranger J, Gilbert E, Drube H: Mucopolysaccharidosis. VII. Beta-glucuronidase deficiency. Humangenetik. 1974 Jul;23[2]:149-158. doi: 10.1007/BF00282212; Cowan T, Pasquali M: Laboratory investigations of inborn errors of metabolism. In: Sarafoglou K, Hoffman GF, Roth KS, eds. Pediatric Endocrinology and Inborn Errors of Metabolism. 2nd ed. McGraw-Hill; 2017:1139-1158)

**PDF Report**

No

**Day(s) Performed**

Preanalytical processing: Monday through Saturday

---

Assay performed: Once per month

**Report Available**

30 to 45 days

**Specimen Retention Time**

WBC homogenate 1 month

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

82657

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
MANN	Alpha-Mannosidase, Leukocytes	24053-1

Result ID	Test Result Name	Result LOINC® Value
35639	Alpha-Mannosidase, Leukocytes	24053-1
35640	Interpretation (MANN)	59462-2
35641	Reviewed By	18771-6